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Abstract 
 
Mutations in the gene encoding dystrophin, a protein that maintains muscle integrity and function, cause 
Duchenne muscular dystrophy (DMD). The deltaE50-MD dog model of DMD harbors a mutation 
corresponding to a mutational “hotspot” in the human DMD gene. We used adeno-associated viruses to deliver 
CRISPR gene editing components to four dogs and examined dystrophin protein expression 6 weeks after 
intramuscular delivery (n = 2) or 8 weeks after systemic delivery (n = 2). After systemic delivery in skeletal 
muscle, dystrophin was restored to levels ranging from 3 to 90% of normal, depending on muscle type. In 
cardiac muscle, dystrophin levels in the dog receiving the highest dose reached 92% of normal. The treated dogs 
also showed improved muscle histology. These large-animal data support the concept that, with further 
development, gene editing approaches may prove clinically useful for the treatment of DMD.  
The persistent contraction and relaxation of cardiac and skeletal muscles necessitates mechanisms that 
maintain the integrity of muscle membranes (1, 2). Dystrophin is a large scaffolding protein that supports 
muscle structure and function by linking the cytoskeleton with the sarcolemma of muscle tissue (1, 3, 4). 
Mutations in the dystrophin gene cause Duchenne muscular dystrophy (DMD), a disorder primarily 
affecting boys that is characterized by progressive muscle degeneration and atrophy, leading to premature 
death from cardiomyopathy and respiratory collapse (5). Thousands of mutations have been identified in the 
dystrophin gene, which spans ~2.5 megabases of DNA and contains 79 exons. Many of these mutations 
cluster into “hotspots,” most commonly in a region that spans exons 45 to 50, typically placing exon 51 out 
of frame with preceding exons and preventing expression of functional dystrophin protein (6, 7). Therapies 
that induce “skipping” of exon 51 restore the reading frame and in principle could benefit ~13% of DMD 
patients (8). An oligo-nucleotide that allows skipping of exon 51 can restore dystrophin expression to 0.22 
to 0.32% of normal levels after 1 year of treatment and has been approved for DMD patients (9–13). 
 
CRISPR-Cas9 gene editing can target DMD mutations and restore dystrophin expression in mice and muscle 
cells derived from human induced pluripotent stem cells (iPSCs) (14–22). An essential step toward clinical 
translation of gene editing as a therapeutic strategy for DMD is the demonstration of efficacy and safety of this 
approach in large mammals. 
 
The mutation carried by the deltaE50-MD canine model of DMD leads to loss of exon 50 and moreover can 
be corrected by skipping of exon 51, making this a valuable model for translational studies. First identified 
as a naturally occurring, spontaneous mutation in Cavalier King Charles Spaniels (23) and now maintained 
on a beagle background, this model (in contrast to mice) exhibits many of the clinical and pathological 
features of the human disease, such as muscle weakness, atrophy, and fibrosis (24). 
 
To correct the dystrophin reading frame in the deltaE50-MD canine model (henceforth referred to as 
ΔEx50) (Fig. 1A), we used Streptococcus pyogenes Cas9 coupled with a single guide RNA (sgRNA) to 
target a region adjacent to the exon 51 splice acceptor site (referred to as sgRNA-51) (Fig. 1B). The 
sgRNA-51 corresponded to a highly conserved sequence that differs by only one nucleotide between the 
human and dog genomes (fig.S1A). Cas9 coupled with each of these sgRNA-51 sequences introduced a 
genomic cut only in DNA of the respective species (fig. S1B). 
 
For the in vivo delivery of Cas9 and sgRNA-51 to skeletal muscle and heart tissue in dogs, we used 
recombinant adeno-associated virus serotype 9 (referred to as AAV9), which displays preferential tropism for 
these tissues (25, 26). A muscle-specific creatine kinase (CK) regulatory cassette was used to drive expression 
of Cas9; three RNA polymerase III promoters (U6, H1, and 7SK) directed expression of the sgRNA, as 
described previously in mice (fig. S2) (18). AAV9-Cas9 and AAV9-sgRNA-51 were initially introduced into 
the cranial tibialis muscles of two 1-month-old dogs by intramuscular injection with 1.2 × 1013 
 
AAV9 viral genomes (vg) of each virus. Muscles were analyzed 6 weeks after injection. In vivo targeting 
efficiency was estimated within muscle biopsy samples by reverse transcription–polymerase chain reaction 
(RT-PCR) with primers for sequences in exons 48 and 53, and genomic PCR amplification products spanning 
the target site were subjected to amplicon deep sequencing. The latter indicated that a mean of 9.96% of total 
reads contained changes at the targeted genomic site, including insertions, deletions, and substitutions (fig. 
S3). The most commonly identified mutations with a mean of 2.35% contained an adenosine (A) insertion 
immediately 3′ to the Cas9 genomic cutting site (Fig. 1C). The deletions identified with this method 
encompassed a highly predicted exonic splicing enhancer (ESE) site for exon 51 (18, 27, 28) (fig. S3A). 
However, this method does not identify larger deletions that might occur beyond the annealing sites of the 
primers used for PCR. Because these tissue samples contain a mixture of muscle and nonmuscle cells, the 
method likely underestimates the efficiency of gene editing within muscle cells. 
 
Sequencing of RT-PCR products of RNA from muscle of ΔEx50 dogs injected intramuscularly with AAV9-
Cas9 and AAV9-sgRNA-51 showed that deletion of exon 51 (ΔEx50–51) allowed splicing from exon 49 to 
52, which restores the dystrophin open reading frame (fig. S3B). On gels, the PCR product with the A 
insertion was indistinguishable in size from non-edited cDNA products, so we performed deep-sequencing 
analysis to quantify its abundance compared to other small insertions. Deep sequencing of the upper band 
containing the non-edited cDNA product and reframed cDNA products indicated that a mean of 73.19% of 
total reads contained reframed cDNA products with an A insertion, a mean of 26.81% contained non-edited 
cDNA product, and the rest contained small deletions and insertions (fig. S3C). However, nonsense-
mediated decay might affect the abundance of non-edited cDNA products. These data indicate that the two 
ΔEx50 dogs injected with AAV9-Cas9 and AAV9-sgRNA-51 had a high frequency of reframing events 
(with cDNA products containing an A insertion in the sequence of exon 51) and exon 51 skipping events 
resulting from deletion of the highly conserved ESE region. 
 
To evaluate the specificity of our gene editing approach, we analyzed predicted off-target genomic sites for 
possible promiscuous editing. A total of three potential genome-wide off- target sites (OT1 to OT3) (fig. S4) 
were predicted in coding exons and four in noncoding regions (fig. S4) by the CRISPR design tool 
(http://crispr.mit.edu/). We performed deep sequencing at the top predicted off-target sites within protein-
coding exons. None of these sites revealed notably more sequence alterations than the background analysis 
performed with other regions of the amplicons (fig. S5). 
 
To evaluate dystrophin correction at the protein level, we performed histological analysis of AAV9-injected 
cranial tibialis muscles 6 weeks after AAV9 injection. Dystrophin immunohistochemistry of muscle from 
ΔEx50 dogs injected with AAV9-Cas9 and AAV9- sgRNA-51 revealed widespread expression: The majority of 
fibers within the injected muscles expressed sarcolemmal dystrophin, albeit to varying levels (Fig. 1D). 
Western blot analysis confirmed the restoration of dystrophin expression in skeletal muscle (Fig. 2, A and B) to 
~60% of wild-type (WT) levels. On average, 2% of WT levels of dystrophin were detected in the uninjected 
contralateral muscles, far more than could be attributed to rare revertant events, which typically represent fewer 
than 0.001% of fibers and are undetectable by Western blot in ΔEx50 muscle. We attribute expression in 
uninjected contralateral muscles to leakage of AAV9 into circulation. As assessed by hematoxylin and eosin 
(H&E) staining, the injected muscles appeared to be normalized relative to muscles of untreated animals, with 
fewer hypercontracted or necrotic fibers, reduced edema and fibrosis, and fewer regions of inflammatory 
cellular infiltration (Fig. 2C). Immunohistochemistry for developmental myosin heavy chain (dMHC), a 
marker of regenerating fibers, revealed a marked reduction in dMHC-positive fibers within injected muscles 
(fig. S6). 
 
Dystrophin nucleates a series of proteins into the dystrophin-associated glycoprotein complex (DGC) to link 
the cytoskeleton and extracellular matrix (3, 4). In ΔEx50 mice, dogs, and DMD patients, these proteins are 
destabilized and do not localize to the subsarcolemmal region (4). Muscles injected with AAV9-Cas9 and 
AAV9-sgRNA-51 showed recovery of the DGC protein β-dystroglycan compared to contralateral uninjected 
muscles (fig. S7). We conclude that—at least in a short time frame of 6 weeks—single-cut genomic editing 
using AAV9-Cas9 and AAV9-sgRNA-51 can efficiently restore dystrophin expression and assembly of the 
DGC in dystrophic muscles. Immunohistochemistry using canine-specific CD4 and CD8 T cell markers (fig. 
S8) showed no evidence of enhanced mono-nuclear cellular infiltration or relevant hematological abnormalities 
in the treated animals compared to untreated controls or reference ranges (fig. S9). 
Based on the high dystrophin-correction efficiency observed after intramuscular injection of AAV9-Cas9 and 
AAV9-sgRNA-51, we tested for rescue of dystrophin expression in two ΔEx50 dogs after systemic delivery of 
gene editing components. The dogs at 1 month of age were injected intravenously with the viruses and analyzed 
8 weeks later. We tested two doses (2 × 1013 vg/kg and 1 × 1014 vg/kg) of each of the two viruses (AAV9-Cas9 
and AAV9- sgRNA-51). To avoid a possible immune reaction, we included a transient regimen of immune 
suppression with the high dose. Systemic delivery of 2 × 1013 vg/kg of each virus (total virus 4 × 1013 vg/kg) in 
ΔEx50-Dog-#2A resulted in expression of virus in peripheral skeletal muscle samples and, to a lower extent, in 
heart samples, as shown by quantitative PCR (qPCR) analysis (fig. S10A). The delivery of 1 × 1014 vg/kg of 
each virus (total virus 2 × 1014 vg/kg) in ΔEx50-Dog-#2B (via infusion) allowed more widespread expression of 
viral constructs in the peripheral skeletal muscle samples and in heart samples (fig. S10B). Systemic delivery of 
AAV9-Cas9 and AAV9-sgRNA-51 led to dystrophin expression in a broad range of muscles, including the heart, 
in gene-edited ΔEx50 dogs at 8 weeks after injection— and to a markedly greater extent than that achieved with 
the lower dose (Fig. 3). To investigate the proportions of various insertions and deletions (indels) generated by 
systemic delivery of AAV9-Cas9 and AAV9-sgRNA-51, we performed amplicon deep- sequencing analysis of 
the genomic DNA from heart, triceps, and biceps muscles. The genomic deep-sequencing analysis revealed an 
increased percentage of reads containing changes at the targeted genomic site, especially of the 1A insertion 
mutation in the samples from Dog-#2B compared to Dog-#2A (fig. S11).  
 
Additionally, we performed tracking indels by decomposition (TIDE) (30) analysis at the genomic and cDNA 
levels, which showed an increase in numbers of indels in the samples from Dog-#2B compared to the samples 
from Dog-#2A (fig. S12). Testes analysis and Western blot analysis showed no activity of Cas9 and confirmed 
muscle-specific expression of gene editing machinery (fig. S13). Western blot analysis confirmed the 
restoration of dystrophin expression in skeletal muscle (Fig. 4, A and B) to ~50, 20, and 3% of WT levels for 
the cranial tibialis, triceps, and biceps, respectively, after systemic delivery of 2 × 1013 vg/kg of each virus 
(total virus 4 × 1013 vg/kg). For Dog-#2B, which received 1 × 1014 vg/kg of each virus (total virus 2 × 1014 
vg/kg), Western blot analysis showed restoration of dystrophin expression (Fig. 4, C and D, and fig. S14) to 
~70, 25, 64, 58, 92, and 5% of WT levels for the cranial tibialis, triceps, biceps, diaphragm, heart, and tongue 
muscles, respectively. Similar to what was seen after intramuscular injection, muscles appeared normalized via 
H&E staining (Fig. 4E). Immunostaining of muscle sections from treated ΔEx50 dogs also showed recovery of 
β-dystroglycan expression (fig. S15) and wide-spread reduction in dMHC (fig. S16). 
 
To determine hematological and biochemical parameters of the treated dogs compared to the controls, we 
collected blood samples the day before injection and then at 1, 2, 4, 6, and 8 weeks after injection. The blood 
samples from all four dogs [healthy untreated, ΔEx50 untreated, and ΔEx50 dogs receiving 2 × 1013 vg/kg of 
each virus (total virus 4 × 1013 vg/kg) and 1 × 1014 vg/kg of each virus (total virus 2 × 1014 vg/kg)] before 
and after injection were unremarkable (fig. S17). Hematology counts, serum electrolytes, and kidney and liver 
function parameters remained within the normal ranges in all dogs. Additionally, blood samples were collected 
weekly for CK assessment: We observed a modest decline in serum CK activity in Dog-#2B treated with 1 × 
1014 vg/kg of each virus (total virus 2 × 1014 vg/kg) (fig. S18) compared to the ΔEx50 untreated dog. 
 
To evaluate the targeting efficiency of a human DMD mutation, we used a DMD iPSC line carrying a deletion 
from exon 48 to 50. Deletion of exons 48 to 50 leads to a frameshift mutation and appearance of a premature 
stop codon in exon 51. To correct the dystrophin reading frame, we introduced two concentrations of Cas9 and 
sgRNA-51 (26 ng/μl, referred to as high, and 13 ng/μl, referred to as low). Indel analysis showed 55.8 and 
31.9% of indels for the high and low concentrations, respectively (fig. S19). Genomic deep-sequencing analysis 
revealed that 27.94% of mutations contained a single A insertion 3′  to the protospacer adjacent motif (PAM) 
sequence for the high concentration condition and 19.03% for the low concentration condition (fig. S20A), as 
observed in mouse and dog cells with a similar sgRNA directed against the same genomic locus. DMD iPSCs 
treated with Cas9 and sgRNA-51 and induced to form cardiomyocytes (iCMs) showed restoration of dystrophin 
immunostaining (fig. S20B) and expression of dystrophin protein to 67 to 100% of the levels of WT 
cardiomyocytes, as measured by Western blot (fig. S20, C and D). 
 
It has been estimated that even 15% of normal levels of dystrophin would provide substantial therapeutic 
benefits for DMD patients (30–32). Our results demonstrate the efficacy of single-cut genome editing for 
restoration of dystrophin expression in a large- animal model of DMD, reaching up to ~80% of WT levels in 
some muscles after 8 weeks. Longer-term studies are required to establish whether the expression of dystrophin 
and the maintenance of muscle integrity that we observed are sustained. 
 
This study, while encouraging, is preliminary and has several limitations, including the relatively small number 
of animals analyzed and the short duration of the analysis (6 to 8 weeks). The possibility of off-target effects of 
in vivo gene editing is a further potential safety concern. Although our initial deep-sequencing analysis of the 
top predicted off-target sites revealed no specific off-target gene editing above background levels in treated 
animals, it will be important to further assess possible off-target mutagenesis in longer-term studies with greater 
numbers of animals. Recent studies reported large deletions and complex genomic rearrangements at target sites 
of CRISPR-Cas9 in mouse embryonic cells, hematopoietic progenitors, and human immortalized epithelial cells 
(33). However, these cells are highly proliferative, are more genomically unstable in culture, and use different 
DNA repair pathways than somatic postmitotic cells (such as muscle and heart cells) (34). Future studies will 
be required to investigate the long-term genomic stability of gene-edited muscle tissues in vivo. Another 
potential concern with CRISPR-Cas9– mediated gene editing in vivo is immunogenicity of Cas9, particularly as 
expression persists after initial treatment. In this short-term study, we did not observe CD4- or CD8-positive 
cell infiltration of treated muscle, but longer-term studies with more sensitive assays must be performed. 
Additionally, although production of large quantities of AAV9 poses a challenge, doses of 2 × 1014vg/kg have 
been successfully used in human gene therapy trials (35). 
 
Finally, although gene editing and exon-skipping oligonucleotides can both restore production of internally 
deleted dystrophin proteins, similar to those expressed in Becker muscular dystrophy, there are key distinctions 
between these approaches. Most notably, CRISPR gene editing may be permanent and not require redelivery, 
whereas oligonucleotides require continuous treatment. A corollary of this is that CRISPR treatment may be 
difficult to terminate if safety concerns arise. 
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